Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: Distinction from enchondroma and identification of progressive tumors

American Journal of Clinical Pathology

Volumn 122, Issue 6, 2004, Pages 912-918

  Helfenstein, Andreas ^a   Frahm, Sven O ^a   Krams, Matthias ^a   Drescher, Wolf ^a   Parwaresch, Reza ^a   Hassenpflug, Joachim ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Chondrosarcoma; Enchondroma; Ki 67; Ki MCM6; Minichromosome maintenance protein 6; Proliferation markers

Indexed keywords

KI 67 ANTIGEN; KI S 2 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 6; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CANCER GRADING; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; ENCHONDROMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABELING INDEX; MALE; PRIORITY JOURNAL;

EID: 9644254095     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/G638TKNNG2CJUXWL     Document Type: Article

References (35)

1. Unni KK. Dahlin's Bone Tumors: General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia, PA: Lippincott-Raven; 1996:71-108.
2. Campanacci M. Bone and Soft Tissue Tumors. 2nd ed. New York, NY: Springer; 1999:213-233.
3. Pritchard DJ, Lunke RJ, Taylor WF, et al. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer. 1980;45:149-157.
4. Jaffe HL. Tumors and Tumorous Conditions of the Bones and Joints. Philadelphia, PA: Lea & Febiger; 1958:314-340.
5. Mirra JM, Gold R, Downs J, et al. A new histologic approach to the differentiation of enchondroma and chondrosarcoma of the bones. Clin Orthop. 1985;201:214-237.
6. Welkerling H, Werner M, Delling G. Histologic grading of chondrosarcoma: a qualitative and quantitative analysis of 74 cases of the Hamburg bone tumor register. Pathologe. 1996;17:18-25.
7. Bjornsson J, McLeod RA, Unni KK, et al. Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998;83:2105-2119.
8. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977;40:818-831.
9. Mirra JM, Eckardt JJ. Enchondroma versus chondrosarcoma. In: Mirra JM, Picci P, eds. Bone Tumors: Clinical, Radiologic and Pathologic Correlations. Vol 1. Philadelphia, PA: Lea & Febiger; 1989:476-535.
10. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
11. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984:133:1710-1715.
12. 2, and M. Blood. 1997;90:226-233.
13. Kreicbergs A, Boquist L, Borssen B, et al. Prognostic factors in chondrosarcoma: a comparative study of cellular DNA content and clinicopathologic features. Cancer. 1982;50:577-583.
14. Vollmer E, Mellin W, Roessner A, et al. Proliferation kinetics of bone tumors. Acta Histochem Suppl. 1990;39:163-174.
15. Scotlandi K, Serra M, Manara MC, et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer. 1995;75:806-814.
16. Nawa G, Ueda T, Mori S, et al. Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer. 1996;69:86-91.
17. Bovee JV, Cleton-Jansen AM, Kuipers-Dijkshoorn NJ, et al. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer. 1999;26:237-246.
18. Bovee JV, van der Heul RO, Taminiau AH, et al. Chondrosarcoma of the phalanx: a locally aggressive lesion with minimal metastatic potential: SL report of 35 cases and a review of the literature. Cancer. 1999;86:1724-1732.
19. Rushing EJ, Armonda RA, Ansari Q, et al. Mesenchymal chondrosarcoma: a clinicopathologic and flow cytometric study of 13 cases presenting in the central nervous system. Cancer. 1996;77:1884-1891.
20. Weinstein LJ, McCarthy EF. Ki-67 immunostaining as a tool in the diagnosis of central cartilage lesions. Iowa Orthop J. 1996;16:39-45.
21. Aigner T, Muller S, Neureiter D, et al. Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas. Cancer. 2002;94:2273-2281.
22. Davis RI, Foster H, Arthur K, et al. Cell proliferation studies in primary synovial chondromatosis. J Pathol. 1998;184:18-23.
23. Bonatz G, Luttges J, Hedderich J, et al. Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: a multivariate study. Hum Pathol. 1999;30:949-956.
24. Rudolph P, Alm P, Heidebrecht HJ, et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst. 1999;91:271-278.
25. Krams M, Heidebrecht HJ, Hero B, et al. Repp86 expression and outcome in patients with neuroblastoma. J Clin Oncol. 2003;21:1810-1818.
26. Rudolph P, Knuchel R, Endl E, et al. The immunohistochemical marker Ki-S2: cell cycle kinetics and tissue distribution of a novel proliferation-specific antigen. Mod Pathol. 1998;11:450-456.
27. Kearsey SE, Labib K. MCM proteins: evolution, properties, and role in DNA replication. Biochim Biophys Acta. 1998;1398:113-136.
28. Labib K, Tercero JA, Diffley JF. Uninterrupted MCM2-7 function required for DNA replication fork progression. Science. 2000;288:1643-1647.
29. Heidebrecht HJ, Buck F, Endl E, et al. Ki-Mcm6, a new monoclonal antibody specific to Memo: comparison of the distribution profile of Memo and the Ki-67 antigen. Lab Invest. 2001;81:1163-1165.
30. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 1999;5:2121-2132.
31. Kreipe H, Alm P, Olsson H, et al. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol. 1993;142:651-657.
32. Rudolph P, Lappe T, Schubert C, et al. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol. 1995;147:1615-1625.
33. Rudolph P, Kellner U, Chassevent A, et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma: a multivariate study. Am J Pathol. 1997;150:1997-2007.
34. Heidebrecht HJ, Adam-Klages S, Szczepanowski M, et al. Repp86: a human protein associated in the progression of mitosis. Mol Cancer Res. 2003;1:271-279.
35. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32:219-229.